Molecules 2013, 18(6), 6491-6503; doi:10.3390/molecules18066491
Article

The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors

1email, 2email, 3email, 3email and 1,* email
1 Institute of Drug Discovery and Development, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China 2 School of Life Sciences, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China 3 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, SIBS, Chinese Academy of Sciences, Shanghai 201203, China
* Author to whom correspondence should be addressed.
Received: 13 May 2013; in revised form: 21 May 2013 / Accepted: 24 May 2013 / Published: 3 June 2013
(This article belongs to the Section Medicinal Chemistry)
PDF Full-text Download PDF Full-Text [258 KB, uploaded 3 June 2013 11:06 CEST]
Abstract: Over the years, the development of targeted medicines has made significant achievements. As a typical example, receptor tyrosine kinases (RTK) inhibitors have become important chemotherapy drugs for a variety of cancers. However, the effectiveness of these agents is always hindered by poor response rates and acquired drug resistance. In order to overcome these limitations, several dual-targeted inhibitors with quinazoline core were designed and synthesized. Though these compounds can simultaneously inhibit histone deacetylases (HDAC) as well as RTK, the structure-activity relationship (SAR) is still not clear enough. To further explore this type of dual-targeted inhibitors, a new class of quinazoline derivatives were designed and synthesized. Their activity evaluations include in vitro inhibitory activity of HDAC, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). The SAR study indicated that the introduction of polar group such as hydroxamate on the 4-position of the quinazoline core is more likely to provide a potent HDACi/HER2i hybrid rather than HDACi/EGFRi molecule.
Keywords: receptor tyrosine kinases; histone deacetylase; antitumor; synergistic effect; dual inhibitor

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Zhang, X.; Su, M.; Chen, Y.; Li, J.; Lu, W. The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors. Molecules 2013, 18, 6491-6503.

AMA Style

Zhang X, Su M, Chen Y, Li J, Lu W. The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors. Molecules. 2013; 18(6):6491-6503.

Chicago/Turabian Style

Zhang, Xuan; Su, Mingbo; Chen, Yi; Li, Jia; Lu, Wei. 2013. "The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors." Molecules 18, no. 6: 6491-6503.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert